A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

BACKGROUND: Access to direct-acting antiviral agents (DAAs) is restricted in some settings; thus, the European Association for the Study of the Liver recommends dual peginterferon/ribavirin (PegIFN/RBV) therapy wherever DAAs are unavailable. HCV genotype (GT) 3 infection is now the most difficult ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Asselah, Tarik, Thompson, Alex J., Flisiak, Robert, Romero-Gomez, Manuel, Messinger, Diethelm, Bakalos, Georgios, Shiffman, Mitchell L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798721/
https://www.ncbi.nlm.nih.gov/pubmed/26991780
http://dx.doi.org/10.1371/journal.pone.0150569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798721/
https://www.ncbi.nlm.nih.gov/pubmed/26991780
http://dx.doi.org/10.1371/journal.pone.0150569

Ejemplares similares